Cochrane Abstracts
Tamoxifen or letrozole versus standard methods for women with estrogen‐receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tamoxifen or Letrozole Versus Standard Methods for Women With Estrogen‐receptor Positive Breast Cancer Undergoing Oocyte or Embryo Cryopreservation in Assisted Reproduction." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435089/all/Tamoxifen_or_letrozole_versus_standard_methods_for_women_with_estrogen_receptor_positive_breast_cancer_undergoing_oocyte_or_embryo_cryopreservation_in_assisted_reproduction:_Cochrane_systematic_review.
Tamoxifen or letrozole versus standard methods for women with estrogen‐receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435089/all/Tamoxifen_or_letrozole_versus_standard_methods_for_women_with_estrogen_receptor_positive_breast_cancer_undergoing_oocyte_or_embryo_cryopreservation_in_assisted_reproduction:_Cochrane_systematic_review. Accessed February 12, 2026.
Tamoxifen or letrozole versus standard methods for women with estrogen‐receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435089/all/Tamoxifen_or_letrozole_versus_standard_methods_for_women_with_estrogen_receptor_positive_breast_cancer_undergoing_oocyte_or_embryo_cryopreservation_in_assisted_reproduction:_Cochrane_systematic_review
Tamoxifen or Letrozole Versus Standard Methods for Women With Estrogen‐receptor Positive Breast Cancer Undergoing Oocyte or Embryo Cryopreservation in Assisted Reproduction [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 February 12]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435089/all/Tamoxifen_or_letrozole_versus_standard_methods_for_women_with_estrogen_receptor_positive_breast_cancer_undergoing_oocyte_or_embryo_cryopreservation_in_assisted_reproduction:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tamoxifen or letrozole versus standard methods for women with estrogen‐receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction
ID - 435089
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435089/all/Tamoxifen_or_letrozole_versus_standard_methods_for_women_with_estrogen_receptor_positive_breast_cancer_undergoing_oocyte_or_embryo_cryopreservation_in_assisted_reproduction:_Cochrane_systematic_review
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
